AU2018232799B2 - Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production - Google Patents

Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production Download PDF

Info

Publication number
AU2018232799B2
AU2018232799B2 AU2018232799A AU2018232799A AU2018232799B2 AU 2018232799 B2 AU2018232799 B2 AU 2018232799B2 AU 2018232799 A AU2018232799 A AU 2018232799A AU 2018232799 A AU2018232799 A AU 2018232799A AU 2018232799 B2 AU2018232799 B2 AU 2018232799B2
Authority
AU
Australia
Prior art keywords
ros
ila
day
production
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018232799A
Other languages
English (en)
Other versions
AU2018232799A1 (en
Inventor
Philippe DIOLEZ
Frédéric MARIN
Olivier Petitjean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Op2 Drugs
Institut National de la Santé et de la Recherche Médicale
Centre Hospitalier Universitaire de Bordeaux
Université de Bordeaux
Original Assignee
Op2 Drugs
Institut National de la Santé et de la Recherche Médicale
Centre Hospitalier Universitaire de Bordeaux
Université de Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Op2 Drugs, Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire de Bordeaux, Université de Bordeaux filed Critical Op2 Drugs
Priority claimed from PCT/EP2018/055651 external-priority patent/WO2018162581A1/en
Publication of AU2018232799A1 publication Critical patent/AU2018232799A1/en
Application granted granted Critical
Publication of AU2018232799B2 publication Critical patent/AU2018232799B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018232799A 2017-03-07 2018-03-07 Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production Ceased AU2018232799B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762467874P 2017-03-07 2017-03-07
EP17159691 2017-03-07
EP17159691.9 2017-03-07
US62/467,874 2017-03-07
PCT/EP2018/055651 WO2018162581A1 (en) 2017-03-07 2018-03-07 Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production

Publications (2)

Publication Number Publication Date
AU2018232799A1 AU2018232799A1 (en) 2019-10-03
AU2018232799B2 true AU2018232799B2 (en) 2021-11-25

Family

ID=61628329

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018232799A Ceased AU2018232799B2 (en) 2017-03-07 2018-03-07 Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production

Country Status (10)

Country Link
US (1) US11484529B2 (enExample)
EP (1) EP3592348A1 (enExample)
JP (1) JP2020511450A (enExample)
KR (1) KR20190129900A (enExample)
CN (1) CN110662535A (enExample)
AU (1) AU2018232799B2 (enExample)
BR (1) BR112019018495A2 (enExample)
CA (1) CA3055122A1 (enExample)
IL (1) IL269127A (enExample)
RU (1) RU2019131478A (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003997A2 (pt) * 2018-09-06 2021-05-25 OP2 Drugs composição farmacêutica compreendendo complexos de ciclodextrina de anetol tritiona ou derivados da mesma
CN112546216B (zh) * 2020-11-20 2022-10-28 西湖大学 小分子化合物奥替普拉在制备增强体液免疫应答的药物中的应用
US20240050402A1 (en) * 2020-12-10 2024-02-15 Frédéric MARIN Anethole trithione administration regimen for the prevention or treatment of ischemia-reperfusion injuries
WO2022171265A1 (en) * 2021-02-09 2022-08-18 Boehringer Ingelheim International Gmbh Modulators of complex i
CN114414332B (zh) * 2022-01-05 2024-04-16 北京科技大学 一种基于Al-CQDs和Al-CNSs的抗氧化剂的制备方法
CN119185368A (zh) * 2024-09-26 2024-12-27 中南大学 具有线粒体序贯靶向能力的强抗氧化性纳米药物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
EP2889294A1 (en) * 2012-08-21 2015-07-01 Soochow University 3h-1,2-dithiocyclopentene-3-thioketone compounds and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030067935A (ko) 2002-02-09 2003-08-19 김상건 올티프라즈를 포함하는 간경화(간경변증) 치료를 위한 간 조직 재생용 제약 조성물
US7076790B2 (en) * 2000-05-22 2006-07-11 Clarion Co., Ltd. Disk player
CN1355156A (zh) * 2000-11-27 2002-06-26 朱国和 含有造纸废料污泥的微生物菌肥及其制备方法
CN1244325C (zh) 2001-05-11 2006-03-08 成都国嘉联合制药有限公司 胆维他在制药中的应用
US7199122B2 (en) 2001-10-02 2007-04-03 Fox Chase Cancer Center Methods for inhibiting angiogenesis
JP2005522446A (ja) 2002-02-13 2005-07-28 ソルベイ・フアルマ 肺癌の化学予防におけるアネトールジチオールチオンの使用
TW200640898A (en) 2005-02-24 2006-12-01 Solvay Pharm Bv Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
EP2125775A4 (en) 2007-03-01 2011-07-13 Cedars Sinai Medical Center ANTIOXIDATION POLYMERS WITH [1,2] -DITHIOLANTEILES AND THEIR USE
CN102961376B (zh) * 2012-11-06 2015-06-10 暨南大学 HMG-CoA还原酶抑制剂氟伐他汀在制备抗淋巴瘤药物中的应用
CN102961375B (zh) 2012-12-05 2015-01-14 苏州大学 一种ampk激活剂及其在制备治疗糖尿病和/或糖尿病并发症的药物中的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
EP2889294A1 (en) * 2012-08-21 2015-07-01 Soochow University 3h-1,2-dithiocyclopentene-3-thioketone compounds and application thereof

Also Published As

Publication number Publication date
RU2019131478A3 (enExample) 2021-07-09
KR20190129900A (ko) 2019-11-20
BR112019018495A2 (pt) 2020-04-14
EP3592348A1 (en) 2020-01-15
JP2020511450A (ja) 2020-04-16
IL269127A (en) 2019-11-28
US11484529B2 (en) 2022-11-01
AU2018232799A1 (en) 2019-10-03
US20210154175A1 (en) 2021-05-27
CN110662535A (zh) 2020-01-07
CA3055122A1 (en) 2018-09-13
RU2019131478A (ru) 2021-04-07

Similar Documents

Publication Publication Date Title
US11318113B2 (en) Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production
US11484529B2 (en) Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production
JP4879152B2 (ja) 代謝調節剤として有用なマロニル−ＣｏＡ脱炭酸酵素阻害剤としてのアゾール
WO2018162581A1 (en) Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production
Lan et al. Design, synthesis and evaluation of resveratrol-indazole hybrids as novel monoamine oxidases inhibitors with amyloid-β aggregation inhibition
US20120129877A1 (en) Use of quinazoline derivatives for neurodegenerative diseases
CN113347972B (zh) 治疗线粒体功能障碍的方法和制剂
JP2016536350A (ja) キヌレニン−３−モノオキシゲナーゼ阻害薬、医薬組成物、及びこれらの使用方法
CA3111886A1 (en) Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof
CN115916337A (zh) 卤代烯丙基胺双胺氧化酶抑制剂
CN110606822A (zh) 具有hsp调节活性的1,4-二氢吡啶衍生物
US10653668B2 (en) Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production
US20030171379A1 (en) Methods of treating, preventing, or inhibiting inflammation with Mactanamide compounds
US20180185325A1 (en) 12H-BENZO[b]XANTHEN-12-ONES, COMPOSITIONS CONTAINING, AND USES OF, SAME
RU2775597C2 (ru) Ингибитор продукции реактивных форм кислорода для лечения заболеваний, связанных со свободными радикалами кислорода
US20180118707A1 (en) Beta-naphthoisoflavones, compositions containing, and uses of, same
KR101896398B1 (ko) 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
KR20110121919A (ko) 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
HK40004138A (en) 2-hydroxy-n-(benzo[d]thiazol-2-yl)benzamide derivatives as mitochondrial uncouplers for the treatment of metabolic diseases and cancer
WO2013052508A1 (en) Compounds and compositions for modulating melanogenesis and pigmentation activities

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired